Skip to main content
Home > BC Innovations > Strategy

Chronological Index of : Strategy

 Current Issue
  • Sunrise in Paris

    How Sanofi brings innovation to its pipeline via the Sanofi-Sunrise initiative

    Through its Sanofi-Sunrise initiative, the pharma is using newco creation as a strategy for accessing external innovation.

    Published on 6/9/2016
  • Table: Academic Angles

    Sanofi's post-reconstruction era Strategy Academic Angles Select academic institutions involved in recent research collaborations with Sanofi (Euronext:SAN; NYSE:SNY). (A) indicates expired or inactive …

    Published on 6/9/2016
  • Table: Preclinical Peek

    Sanofi's post-reconstruction era Strategy Preclinical Peek Although Sanofi (Euronext:SAN; NYSE:SNY) isn't making its complete preclinical pipeline public, the pharma has disclosed several preclinical programs, some…

    Published on 6/9/2016
  • Table: Sunrise View

    Sunrise in Paris Strategy Sunrise View The Sanofi-Sunrise initiative is a company-creation vehicle from Sanofi (Euronext:SAN; NYSE:SNY) that funds new companies to accelerate development of early stage technologies…

    Published on 6/9/2016
  • Digital Preclinical

    How Vium is automating data collection to overhaul in vivo research practices

    Vium is using its techie founders' Silicon Valley know-how to overhaul animal research and increase reproducibility in preclinical studies.

    Published on 6/2/2016
  • Box: Set to launch

    Mind the gap Strategy Set to launch The U.K. government's technology strategy board, renamed Innovate U.K., has created a Catapult Programme composed of 11 centers, each focused on accelerating a different …

    Published on 5/19/2016
  • Mind the gap

    U.K. keeps calm and boosts translational science

    The U.K. is boosting biotech with a slew of new investments and initiatives to help universities spin out discoveries rather than primarily license them to pharmas.

    Published on 5/19/2016
  • Throw CRISPR into a pool

    CRISPR-Cas9 is a research tool that should be shared through a patent pool

    Editors' Commentary: Instead of litigating, CRISPR's pioneers should throw their patents in a pool and compete to invent new medicines.

    Published on 4/28/2016
  • All change at King's Cross

    How The Crick wants to kick-start translation in the U.K.

    The Crick's David Roblin wants the new institute to catapult the U.K. to the big leagues in translational science.

    Published on 4/28/2016
  • Next stop: Houston

    How JLABS' new site at TMC plays into Houston's hub hopes

    While JLABS' new site at the Texas Medical Center is a welcome investment in the region, Houston is still in the early days of its quest to become the next U.S. biotech hub.

    Published on 4/14/2016
  • Figure: Companies formed

    Next stop: Houston Strategy Companies formed Total number of new biopharma companies formed in multiple regions of the U.S. from 2010 to 2016. Source: BCIQ: BioCentury Online Intelligence

    Published on 4/14/2016
  • Figure: Seed and series A funding

    Next stop: Houston: Figure: Seed and series A funding Next stop: Houston Strategy Seed and series A funding Seed and series A funding amounts for each region from 2010 to 2016. Total values include all disclosed …

    Published on 4/14/2016
  • Figure: Tri-coastal Spread

    Next stop: Houston Strategy Tri-coastal Spread Total National Institutes of Health (NIH) funding for select academic institutions in the San Francisco Bay Area (blue); Boston and Cambridge, Mass. (green); and …

    Published on 4/14/2016
  • Table: Homing to Houston

    Next stop: Houston Strategy Homing to Houston Founding companies in the JLABS @ TMC incubator at the Texas Medical Center (TMC) focused on therapeutics and diagnostics. The table does not include companies focused …

    Published on 4/14/2016
  • Figure: Coordinated attack

    Combo platter Strategy Coordinated attack Incyte Corp. (NASDAQ:INCY) is taking a pathway-based approach to building its pipeline by selecting targets that yield coordinated benefit if attacked simultaneously. The …

    Published on 3/24/2016
  • Figure: Mix and match

    Combo platter Strategy Mix and match Incyte Corp. (NASDAQ:INCY) is building a portfolio of anticancer compounds designed to have maximal synergies with each other. With the March announcement of its OX40-targeted …

    Published on 3/24/2016
  • Combo platter

    How Incyte aims to discover high synergy combo therapies

    Instead of playing catch-up to find cancer combos once molecules reach the clinic, Incyte is building combo-thinking into its preclinical strategy from the outset.

    Published on 3/24/2016
  • Transcending TransCelerate

    TransCelerate's preclinical move into toxicology

    TransCelerate has created the subsidiary BioCelerate to expand its reach into the preclinical space, starting with toxicology.

    Published on 3/17/2016
  • Table: Toxicology data initiatives

    Transcending TransCelerate Strategy Toxicology data initiatives Selected toxicology-centered consortia with large data-sharing components. Although several older groups are already well established, BioCelerate …

    Published on 3/17/2016
  • Changing the channel

    A new open-science platform aims to spotlight reproducibility

    Researchers can now publish their attempts to reproduce each other's data on a new channel that's the brainchild of leaders from Amgen and F1000.

    Published on 2/25/2016
  • Table: Reproducibility initiatives

    Changing the channel Strategy Reproducibility initiatives The low reproducibility of published preclinical research - often dubbed the "reproducibility crisis" - has sparked several initiatives from publicly funded…

    Published on 2/25/2016
  • CIRM's endgame

    CIRM plots its final years with new strategic plan

    CIRM's new strategic plan lays out internal changes and external challenges for its final five years.

    Published on 1/28/2016
  • Figure: CIRM Grant Totals

    CIRM's endgame Strategy CIRM Grant Totals Totals for all program areas funded by California Institute for Regenerative Medicine (CIRM). CIRM was founded in 2004 but did not award its first grants until 2006 because…

    Published on 1/28/2016
  • Figure: CIRM Grant Totals

    CIRM's endgame Strategy CIRM Grant Totals Totals for all program areas funded by California Institute for Regenerative Medicine (CIRM). CIRM was founded in 2004 but did not award its first grants until 2006 because…

    Published on 1/28/2016
  • Figure: Sucky at the Castle Gate

    ' Commentary Sucky at the Castle Gate Reproduced with permission from RedPen/BlackPen

    Published on 1/28/2016

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993